What is Shionogi & Co., Ltd. (SGIOY)?

Shionogi & Co., Ltd. (SGIOY) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of SGIOY?

The current price of SGIOY is $9.52. Prices are updated in real time on Stocks360.

What is SGIOY's price-to-earnings (PE) ratio?

SGIOY's trailing twelve-month PE ratio is 10.63, based on current price and earnings per share data available on Stocks360.

What is SGIOY's market capitalization?

SGIOY's market capitalization is $16,206,340,451.00, placing it in the large-cap tier.

Does SGIOY pay a dividend?

Yes. SGIOY has a trailing twelve-month dividend yield of 0.03%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Shionogi & Co., Ltd. (SGIOY)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$9.52

Market Cap

$16.21B

PE (TTM)

10.63

EPS (TTM)

N/A

Dividend Yield

2.59%

Beta

0.03

Day Range

$9.49 – $9.58

52-wk Range

$8.11 – $12.00

Avg Volume

N/A

Volume

1.92K

Shionogi & Co., Ltd. (SGIOY) is a publicly traded company in the Healthcare sector. Latest price: $9.52. Market cap $16.21B. Trailing PE 10.63. Dividend yield 2.59%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $8.26 2026-10-30 · $9.52 (+15.25%)

Earnings

Most Recent

Oct 29, 2026

EPS $0.08 vs est. $0.13

Missed by $0.05

Next Earnings

Jan 29, 2027

EPS estimate $0.18

Proprietary Signals

Signal snapshot temporarily unavailable.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. The firm markets several key therapeutic agents, including Fetroja, a crucial therapy for multi-drug resistant gram-negative bacterial infections; Xofluza, an antiviral medication for influenza; and Tivicay, an effective anti-HIV agent. Shionogi also maintains an extensive research and development pipeline, with numerous compounds under investigation for various conditions. Its development portfolio includes treatments for opioid-induced constipation (Symproic), various pain types such as inflammatory pain (S-120083), neuropathic pain (S-010887, sivopixant), and neuropathic low back pain (S-637880). Sivopixant is additionally being explored for sleep apnea syndrome and refractory/unexplained chronic cough. In neuroscience, the company is advancing S-117957 for insomnia, Zuranolone for depression, SDT-001 for attention-deficit/hyperactivity disorder, and BPN14770 for Fragile X syndrome and Alzheimer's disease. Furthermore, it is developing S-237648 a…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	10.63×
P/S (TTM)	4.02×
P/B	1.47×
PEG	0.26×
P/FCF (TTM)	10.41×
EV / EBITDA	9.50×
EV / Sales	4.51×
Earnings Yield	9.40%
Free Cash Flow Yield	9.61%
Dividend Yield	2.59%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.87T
Revenue (TTM)	$637.09B
Net Income (TTM)	$241.07B
Free Cash Flow (TTM)	$246.62B
Net Debt	$306.51B
Working Capital	$199.04B
Gross Margin	76.09%
Operating Margin	28.72%
Net Margin	37.85%
Return on Equity	14.36%
Return on Invested Capital	7.20%